Media-News

Be the most trusted biotech company

2025-12-12

China NMPA Accepts NDA and Grants Priority Review to Serplulimab for Neo-/Adjuvant Treatment of Gastric Cancer
2025-12-10

Henlius Highlights Dual Progress in Breast Cancer Pipeline as HLX11 and HLX78 Data Release at ESMO Asia 2025
2025-12-08

Henlius Unveils Multi-Disciplinary Research on Serplulimab at ESMO Asia, Demonstrating Broad Clinical Value
2025-12-07

Henlius' Six Products included in China's National Reimbursement Drug List, with Innovative Breast Cancer Drug FUTUONING Added for the First Time
2025-12-05

Henlius' PD-L1 ADC HLX43 Cervical Cancer Data Debuts as Proffered Paper at 2025 ESMO Asia
2025-11-26

Henlius to Present Diverse Solid Tumor Pipeline at 2025 ESMO Asia: Phase 2 Cervical Cancer Data for PD-L1 ADC HLX43 Featured in Proffered Paper
2025-11-25

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Proposed Ipilimumab Biosimilar
2025-11-21

Henlius Participates in the 2025 Jefferies Global Healthcare Conference in London
2025-11-21

Henlius' Serplulimab (anti-PD-1 mAb) Granted Breakthrough Therapy Designation by China NMPA for Neo-/Adjuvant Treatment for Gastric Cancer